Outlook Therapeutics has announced the Scottish Medicines Consortium (SMC) approval of Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD). Lytenava is the first and only licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and UK. The SMC recommendation follows news of Lytenava […]
The post Treatment for serious eye disease approved in Scotland appeared first on Pharmafile.
